For nearly a century, scientists have watched underfed lab animals outlive their well-fed counterparts. Worms, flies, mice, and monkeys that eat less tend to age more slowly and die later. The pattern is one of the most replicated findings in biology. What nobody could say, until recently, was whether the same trick works in people.
Now there is a real answer, or at least the beginning of one. A molecular analysis of blood samples from the CALERIE trial, published in Nature Aging, found that healthy adults who sustained a calorie deficit for two years showed a measurable slowdown in a DNA methylation-based marker of biological aging. It is the first randomized human evidence that cutting calories can slow the molecular machinery of growing old.
Inside the CALERIE trial
CALERIE stands for Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy. Registered on ClinicalTrials.gov, the Phase 2 trial was a multi-center randomized controlled study that enrolled 218 healthy, non-obese adults between the ages of 21 and 50. Participants were assigned either to aim for a 25 percent daily calorie reduction or to continue eating normally. The intervention lasted 24 months.
Hitting that 25 percent target turned out to be hard. According to the trial’s feasibility report in the Journals of Gerontology, participants in the restriction group achieved an average reduction of roughly 12 percent, about half the goal. That gap matters: whatever aging effects showed up came not from a dramatic fast but from a moderate, sustained cut of a few hundred calories a day.
The trial’s primary outcomes tracked weight, metabolic markers, and safety over the full two years. Calorie restriction produced significant weight loss and improvements in cardiometabolic risk factors, but it also carried trade-offs. Some participants experienced decreases in bone mineral density and mild anemia, side effects that underscore why blanket recommendations for long-term restriction remain premature.
What the aging clock found
The aging analysis came later. Researchers applied a biomarker called DunedinPACE to stored blood samples from the trial. Unlike epigenetic clocks that estimate a person’s biological “age” as a single number, DunedinPACE measures the speed at which aging-related decline is happening in real time. It was built from longitudinal health data in the Dunedin birth cohort in New Zealand, tracking organ-system deterioration across cardiovascular, metabolic, renal, hepatic, and immune functions, as described in its validation paper in eLife.
The result: participants in the calorie-restriction group showed a roughly 2 to 3 percent slowing on the DunedinPACE scale compared with controls. That may sound modest, but the researchers noted that even small shifts in the pace of aging, sustained over years, could compound into meaningful differences in disease risk and lifespan at the population level. The finding held after adjusting for baseline differences and was statistically significant.
Because CALERIE was a randomized controlled trial, the result carries more weight than observational studies linking diet to aging markers. Participants were assigned to groups rather than self-selecting, which reduces the chance that pre-existing health differences explain the outcome. Pairing that trial design with a rigorously validated molecular clock is what makes this finding qualitatively different from earlier work.
What the data cannot tell us yet
A slower aging clock is not the same as a longer life. The most important caveat is that no published data from CALERIE show whether participants who experienced the DunedinPACE slowdown went on to develop fewer age-related diseases or actually lived longer. Biomarker movement and clinical outcomes are related but not identical, and bridging that gap requires years of follow-up that have not yet appeared in the published record.
The analysis was also post-hoc. CALERIE was not originally designed with DunedinPACE in mind; the clock was developed after the trial ended and then applied to banked samples. That approach is standard in aging research, where new biomarkers regularly emerge after data collection is complete, but it raises the bar for replication. Independent teams will need to apply the same or similar clocks to other intervention trials before the finding can be considered settled.
Population scope is another limitation. CALERIE enrolled healthy, non-obese adults willing to stick with a demanding protocol for two years. People with chronic illness, older adults with frailty, or anyone with a history of disordered eating were excluded. Whether calorie restriction would produce the same molecular signal in those groups, or whether it would be safe to try, remains unknown.
And then there is the practical question millions of readers will ask: is this the same as intermittent fasting or time-restricted eating? It is not. CALERIE tested a sustained, daily reduction in total calorie intake, not a pattern of skipping meals or compressing eating into a narrow window. The two approaches may overlap in some metabolic effects, but they have not been directly compared in a trial designed to measure aging speed.
Where the science goes from here
The CALERIE biobank, housed at the NIA Aging Research Biobank, still holds a trove of unanalyzed material: genotypes, longitudinal DNA methylation profiles, mRNA and small RNA measurements from blood, and in subsets of participants, tissue samples from muscle and fat. Qualified researchers can request access, and as of June 2026, several groups are working with those datasets to explore how gene expression, metabolites, and tissue-specific methylation patterns connect to the blood-based clock signal.
Long-term follow-up of the original participants, if it can be organized and funded, would be the single most valuable next step. Tracking whether those with slower DunedinPACE trajectories actually experience fewer heart attacks, cancers, or cognitive declines would convert a promising biomarker finding into actionable medical evidence.
Trials comparing calorie restriction head-to-head with exercise, time-restricted eating, or drugs targeting similar metabolic pathways (like rapamycin analogs or metformin) could also clarify whether eating less is uniquely powerful or simply one of several routes to a slower aging pace.
Why the CALERIE clock result matters without yet changing medical advice
The CALERIE result occupies a specific and significant place in aging science: it is the strongest mechanistic evidence to date that reducing calorie intake slows biological aging in humans. But it stops short of proving that people who eat less will live longer, avoid disease, or feel better over decades. Anyone considering a major dietary change based on this research should weigh the molecular promise against the real-world difficulty of sustained restriction and the side effects documented in the trial itself. The clock has slowed. Whether that translates into more healthy years is the question the next generation of studies will have to answer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
